Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib works in treating patients with biliary tract
cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair
gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.